Tarsus Pharmaceuticals (TARS) News Today $47.84 -0.88 (-1.81%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$47.86 +0.02 (+0.05%) As of 02/21/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025February 20 at 5:00 PM | globenewswire.comNations Financial Group Inc. IA ADV Takes $332,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Nations Financial Group Inc. IA ADV purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 6,000 shares of the company's stock, valFebruary 19 at 4:03 AM | marketbeat.comAllspring Global Investments Holdings LLC Has $10.03 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Allspring Global Investments Holdings LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 181,122 shares of the companFebruary 19 at 3:37 AM | marketbeat.comTarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on TuesdayTarsus Pharmaceuticals (NASDAQ:TARS) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $56.00 Consensus Target Price from BrokeragesFebruary 15, 2025 | americanbankingnews.comBleakley Financial Group LLC Purchases Shares of 5,825 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Bleakley Financial Group LLC purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 5,825 shares of the company's stock, valued at approximately $323,00February 12, 2025 | marketbeat.comGuggenheim Reiterates Buy Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)February 12, 2025 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned a consensus rating of "Buy" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy ratingFebruary 12, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Receives "Buy" Rating from GuggenheimGuggenheim reissued a "buy" rating on shares of Tarsus Pharmaceuticals in a report on Monday.February 10, 2025 | marketbeat.comabrdn plc Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)abrdn plc lowered its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 93,650 shares of the company's stock after selling 8,905 shaFebruary 10, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 5.3% - Here's What HappenedTarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 5.3% - Time to Sell?February 6, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 12-Month High - Should You Buy?Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High - Here's What HappenedFebruary 5, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by E. Ohman J or Asset Management ABE. Ohman J or Asset Management AB trimmed its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,781 shares of the compaFebruary 5, 2025 | marketbeat.comBreakeven On The Horizon For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)February 4, 2025 | finance.yahoo.comJennison Associates LLC Acquires 321,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,500,132 shares of the company's stock after buyingFebruary 3, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesJanuary 30, 2025 | globenewswire.comBarclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)January 27, 2025 | markets.businessinsider.comTarsus Pharmaceuticals price target raised to $62 from $60 at BarclaysJanuary 27, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading 9% Higher Following Analyst UpgradeTarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 9% on Analyst UpgradeJanuary 27, 2025 | marketbeat.comBarclays Issues Positive Forecast for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock PriceBarclays lifted their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an "overweight" rating in a research note on Monday.January 27, 2025 | marketbeat.comTarsus: Promising Investment, But Timing Is The KeyJanuary 24, 2025 | seekingalpha.comOppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potentialJanuary 23, 2025 | msn.comOppenheimer Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) StockOppenheimer increased their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday.January 22, 2025 | marketbeat.comIs Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?January 20, 2025 | insidermonkey.comTarsus Pharmaceuticals reshuffles board, appoints new committee chairJanuary 18, 2025 | msn.comGrant GrossMendelsohn LLC Has $2.18 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Grant GrossMendelsohn LLC lessened its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 39,299 shares of the company's stock after selling 14,331 shares during the quarter.January 18, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Buy" from BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recoJanuary 18, 2025 | marketbeat.comTarsus Pharmaceuticals: Strong Market Penetration and Promising Expansion into Ocular RosaceaJanuary 16, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (TARS) Receives a Buy from BarclaysJanuary 16, 2025 | markets.businessinsider.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Assenagon Asset Management S.A.Assenagon Asset Management S.A. increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,146,812 shares of tJanuary 16, 2025 | marketbeat.comTarsus Pharmaceuticals provides 2025 updateJanuary 14, 2025 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)January 14, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 6.3% - Here's What HappenedTarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 6.3% - Should You Sell?January 14, 2025 | marketbeat.comTarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye CareJanuary 13, 2025 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - What's Next?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Should You Sell?January 13, 2025 | marketbeat.comTarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye CareJanuary 13, 2025 | globenewswire.comJPMorgan Chase & Co. Has $14.48 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)JPMorgan Chase & Co. grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2,088.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 440,167 shares of the company's stock after acquirJanuary 11, 2025 | marketbeat.comTarsus Pharmaceutical - Eye Care TherapeuticsJanuary 2, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High - Here's What HappenedTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High - Still a Buy?December 30, 2024 | marketbeat.comGeode Capital Management LLC Increases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Geode Capital Management LLC boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 8.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 835,790 shares of the company's stock after buying an additional 6December 27, 2024 | marketbeat.comThe Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDexDecember 26, 2024 | finance.yahoo.comHow Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit RunDecember 26, 2024 | yahoo.comBarclays PLC Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Barclays PLC boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 345.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 98,663 shares of the company's stock after purcDecember 24, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by State Street CorpState Street Corp lowered its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 899,379 shares of the company's stocDecember 22, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (A) and Teva Pharmaceutical (TEVA)December 18, 2024 | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Still a Buy?Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High - Here's What HappenedDecember 18, 2024 | marketbeat.comWellington Management Group LLP Has $4.78 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Wellington Management Group LLP increased its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 145,347 shares of the coDecember 17, 2024 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Lord Abbett & CO. LLCLord Abbett & CO. LLC lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 28.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 594,876 shares of the company's stock afterDecember 16, 2024 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Should You Sell?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - What's Next?December 13, 2024 | marketbeat.comTarsus Pharmaceuticals: Early Rollout Exceeding ExpectationsDecember 10, 2024 | seekingalpha.com Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼0.870.60▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼44▲TARS Articles Average Week Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Legend Biotech News BridgeBio Pharma News Axsome Therapeutics News Blueprint Medicines News Telix Pharmaceuticals Limited American Depositary Shares News Elanco Animal Health News Lantheus News Nuvalent News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts